COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS

Objective: To compare the efficacy of tacrolimus 0.03% ointment to olopatadine 0.2% eye drops in the treatment of vernal keratoconjunctivitis. Study Design: Prospective cross-sectional study. Place and Duration of Study: Eye Department Combined Military Hospital Quetta, from Feb to Jul 2019....

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hassan Sajjad Rathore, Shahzad Saeed, M. Ahsan Mukhtar, Umar Ijaz, Asad Habib, Iqra Ghaus
Formato:	article
Lenguaje:	EN
Publicado:	Army Medical College Rawalpindi 2021
Materias:	vernal keratoconjunctivitis tacrolimus olopatadine Medicine R Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fb9a8d47b3b7483183731ea49a9c696e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fb9a8d47b3b7483183731ea49a9c696e
record_format	dspace
spelling	oai:doaj.org-article:fb9a8d47b3b7483183731ea49a9c696e2021-12-02T18:44:46ZCOMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS0030-96482411-884210.51253/pafmj.v71i1.3251https://doaj.org/article/fb9a8d47b3b7483183731ea49a9c696e2021-02-01T00:00:00Zhttps://pafmj.org/index.php/PAFMJ/article/view/3251https://doaj.org/toc/0030-9648https://doaj.org/toc/2411-8842Objective: To compare the efficacy of tacrolimus 0.03% ointment to olopatadine 0.2% eye drops in the treatment of vernal keratoconjunctivitis. Study Design: Prospective cross-sectional study. Place and Duration of Study: Eye Department Combined Military Hospital Quetta, from Feb to Jul 2019. Methodology: A total of 69 patients with active vernal keratoconjunctivitis (VKC) were included in this study. Thirty six (52.17%) patients were randomized in tacrolimus group and 33 (47.83%) in olopatadine group B. Baseline values of the subjective symptom score (SSS) and the objective sign score (OSS) were noted. Patients were reviewed on weeks 2, 4, 8 and 12 and the scores at each visit were summed. These scores were used for comparison between groups. Results: At the start of the study, the mean subjective symptoms score and objective sign score of group A was 9.0 ± 2.04 and 3.93 ± 1.93 respectively, while that of group B was 8.88 ± 2.18 and 4.36 ± 1.90 respectively. At the end of 12-weeks, the mean subjective symptoms score and objective sign score of group A reduced to 0.11 ± 0.32 and 0.08 ± 0.28 respectively, while that of group B reduced to 1.70 ± 0.77 and 0.64 ± 0.55 respectively. Total improvement of scores (as a percentage of baselines) among tacrolimus group was 98.3% and olopatadine group was 83%. Conclusion: Although both 0.03% tacrolimus and 0.2% olopatadine were effective in improving the signs and symptoms of VKC, 0.03% tacrolimus was significantly superior.Hassan Sajjad RathoreShahzad SaeedM. Ahsan MukhtarUmar IjazAsad HabibIqra GhausArmy Medical College Rawalpindiarticlevernal keratoconjunctivitistacrolimusolopatadineMedicineRMedicine (General)R5-920ENPakistan Armed Forces Medical Journal, Vol 71, Iss 1, Pp 34-39 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	vernal keratoconjunctivitis tacrolimus olopatadine Medicine R Medicine (General) R5-920
spellingShingle	vernal keratoconjunctivitis tacrolimus olopatadine Medicine R Medicine (General) R5-920 Hassan Sajjad Rathore Shahzad Saeed M. Ahsan Mukhtar Umar Ijaz Asad Habib Iqra Ghaus COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
description	Objective: To compare the efficacy of tacrolimus 0.03% ointment to olopatadine 0.2% eye drops in the treatment of vernal keratoconjunctivitis. Study Design: Prospective cross-sectional study. Place and Duration of Study: Eye Department Combined Military Hospital Quetta, from Feb to Jul 2019. Methodology: A total of 69 patients with active vernal keratoconjunctivitis (VKC) were included in this study. Thirty six (52.17%) patients were randomized in tacrolimus group and 33 (47.83%) in olopatadine group B. Baseline values of the subjective symptom score (SSS) and the objective sign score (OSS) were noted. Patients were reviewed on weeks 2, 4, 8 and 12 and the scores at each visit were summed. These scores were used for comparison between groups. Results: At the start of the study, the mean subjective symptoms score and objective sign score of group A was 9.0 ± 2.04 and 3.93 ± 1.93 respectively, while that of group B was 8.88 ± 2.18 and 4.36 ± 1.90 respectively. At the end of 12-weeks, the mean subjective symptoms score and objective sign score of group A reduced to 0.11 ± 0.32 and 0.08 ± 0.28 respectively, while that of group B reduced to 1.70 ± 0.77 and 0.64 ± 0.55 respectively. Total improvement of scores (as a percentage of baselines) among tacrolimus group was 98.3% and olopatadine group was 83%. Conclusion: Although both 0.03% tacrolimus and 0.2% olopatadine were effective in improving the signs and symptoms of VKC, 0.03% tacrolimus was significantly superior.
format	article
author	Hassan Sajjad Rathore Shahzad Saeed M. Ahsan Mukhtar Umar Ijaz Asad Habib Iqra Ghaus
author_facet	Hassan Sajjad Rathore Shahzad Saeed M. Ahsan Mukhtar Umar Ijaz Asad Habib Iqra Ghaus
author_sort	Hassan Sajjad Rathore
title	COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
title_short	COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
title_full	COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
title_fullStr	COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
title_full_unstemmed	COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
title_sort	comparative evaluation of tacrolimus 0.03% ointment vs olopatadine 0.2% eye drops in the treatment of vernal keratoconjunctivitis
publisher	Army Medical College Rawalpindi
publishDate	2021
url	https://doaj.org/article/fb9a8d47b3b7483183731ea49a9c696e
work_keys_str_mv	AT hassansajjadrathore comparativeevaluationoftacrolimus003ointmentvsolopatadine02eyedropsinthetreatmentofvernalkeratoconjunctivitis AT shahzadsaeed comparativeevaluationoftacrolimus003ointmentvsolopatadine02eyedropsinthetreatmentofvernalkeratoconjunctivitis AT mahsanmukhtar comparativeevaluationoftacrolimus003ointmentvsolopatadine02eyedropsinthetreatmentofvernalkeratoconjunctivitis AT umarijaz comparativeevaluationoftacrolimus003ointmentvsolopatadine02eyedropsinthetreatmentofvernalkeratoconjunctivitis AT asadhabib comparativeevaluationoftacrolimus003ointmentvsolopatadine02eyedropsinthetreatmentofvernalkeratoconjunctivitis AT iqraghaus comparativeevaluationoftacrolimus003ointmentvsolopatadine02eyedropsinthetreatmentofvernalkeratoconjunctivitis
_version_	1718377717960802304

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS

Ejemplares similares